JNJ-88545223

Phase 2Small molecule

Johnson & Johnson

JNJ-88545223 is one of 5 small molecule programs targeting Arthritis, Psoriatic. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Arthritis, PsoriaticRecruiting

Arthritis, PsoriaticPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Arthritis, Psoriatic

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Approved

6 2

Otezla

Amgen

Approved

1 3

Icotyde

Johnson & Johnson

Phase 3

2 4

Sonelokimab

MMoonLake Immunotherapeutics AG

Phase 3

4 5

JNJ-88545223

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Arthritis, Psoriatic

NCT07321873

Clinical

Trials by Indication[1]

Arthritis, Psoriatic1 trial

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 For the Treatment of Participants With Active Psoriatic Arthritis

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT07321873·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JNJ-88545223. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-88545223 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-88545223. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

JNJ-88545223

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Arthritis, Psoriatic1 trial

References

Drug Info

Quick Facts

Related News